Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus amylovorus

What does the research say about Lactobacillus amylovorus?

3 health outcomes synthesised

Lactobacillus amylovorus has been researched for 3 health outcomes: improved growth performance, reduced inflammation, and improved intestinal barrier function. The strongest evidence, though limited, comes from 4 animal studies on growth performance, all reporting benefits but with mixed effect sizes and no consistent dose identified. All research is currently in non-human animal models, and no human trials have been conducted.

Strongest evidence None of the synthesized outcomes reached moderate or high evidence strength. The strongest relative evidence is for Improved Growth Performance (4 studies, low evidence strength). All 4 studies reported beneficial effects on weight gain or feed efficiency in young livestock (weaning pigs, newborn piglets/mice, weaned lambs) and one fish study. Effect sizes ranged from small to large, but no effective dose range could be determined because doses were not reported in any study.

Mixed or weaker evidence Reduced Inflammation (4 studies, low evidence) showed beneficial effects in all studies, but the data are heterogeneous. One meta-analysis reported a small effect on C-reactive protein (CRP), while other studies involved indirect interventions (e.g., Bacillus subtilis or epigallocatechin) or in vitro human monocytes. Improved Intestinal Barrier Function (3 studies, very low evidence) reported moderate benefits on tight junction genes and villus height, all in animal models (piglets, sows, lambs). Two of the three studies are flagged as future/placeholder entries from 2026, and one used a different substance (EGC), weakening the link to L. amylovorus.

Effective dose patterns No cross-cutting dose insights are possible because no effective dose range was reported in any of the 11 studies across the three syntheses. The database entries consistently note a missing dose field.

Population insights The majority of research involves young livestock (weaning pigs, newborn piglets, weaned lambs). One study used Asian seabass fingerlings. No human populations have been studied. No consistent population segment can be identified for inflammation or barrier function outcomes due to incomplete reporting.

Notable caveats

  • All evidence comes from non-human animal models; human trials are absent.
  • Several studies had low methodological quality (evidence scores of 0) or involved interventions not directly with L. amylovorus (e.g., Bacillus subtilis, EGC).
  • Doses, forms, and study durations were often not reported, making replication and clinical translation impossible.
  • Two studies for intestinal barrier function are future-dated (2026), raising credibility concerns.

Frequently asked

  • What is Lactobacillus amylovorus good for according to research?
    Current research on Lactobacillus amylovorus covers three outcomes: improved growth performance, reduced inflammation, and improved intestinal barrier function. All outcomes have shown beneficial effects in animal studies, but the evidence is rated low or very low, and no human trials have been conducted. Growth performance has the most studies (4) and the highest relative evidence strength.
  • What dose of Lactobacillus amylovorus is typically used in studies?
    No specific dose range has been reported consistently across the 11 studies reviewed. The database entries note that the dose of Lactobacillus amylovorus was not reported in any study, making it impossible to identify a typical or effective dose. This is a major limitation for translating findings to human use.
  • Who benefits most from Lactobacillus amylovorus?
    All studies have been conducted in non-human animal populations. For growth performance, young livestock (weaning pigs, newborn piglets, weaned lambs) and one fish species showed benefits. No human populations have been studied, so it is not possible to identify a specific human group that benefits most.
  • Are there caveats or limitations in the research on Lactobacillus amylovorus?
    Yes. All evidence is from animal models; no human trials exist. Many studies have low methodological quality, and some interventions used other substances (e.g., Bacillus subtilis, epigallocatechin) rather than L. amylovorus alone. Doses and study details are frequently unreported, and two of the three intestinal barrier studies are from 2026 (future-dated), which limits credibility.
  • Does Lactobacillus amylovorus help with reducing inflammation?
    Four studies reported beneficial effects on inflammation, but the evidence is low. Effect sizes were mixed (small to moderate). The highest-quality study – a meta-analysis – found a small reduction in C-reactive protein (CRP). However, two of the four studies did not directly involve L. amylovorus supplementation, and one was in vitro, so results should be interpreted cautiously.
  • Does Lactobacillus amylovorus improve intestinal barrier function?
    Three animal studies reported moderate beneficial effects on intestinal barrier function, including improvements in tight junction gene expression and villus height. However, the evidence strength is very low due to limitations: two studies are future-dated (2026), one used a different substance (EGC), and all were in pig or lamb models. No human evidence is available.

Most-studied combinations with Lactobacillus amylovorus

most supplement research is combination research
Also studied with:Lactobacillus acidophilus (2)
Back to top